# Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

> **NCT07661056** · PHASE3 · RECRUITING · sponsor: **Biohaven Therapeutics Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Graves Disease

## Interventions

- **DRUG:** BHV-1300
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07661056
- **Lead sponsor:** Biohaven Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-26
- **Primary completion:** 2028-01
- **Final completion:** 2028-02
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661056, "Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07661056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*